RxDoctor Payments Data

Leopoldo Tecuanhuey, MD

Nephrology · San Antonio, TXNPI 1083616197

Payments from drug & device makers

$2,572in general payments, 2019–2025

Across 74 payments — averaging $34.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$867
  • Amgen$748
  • AstraZeneca$334
  • Mallinckrodt Hospital Products Inc.$257
  • Mallinckrodt Enterprises LLC$166
  • Aurinia Pharma U.S., Inc.$110
  • plus $91 from 2 others

What the payments were for

  • Food & beverage$2,55599%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,572 in reported general payments places this provider in the 55th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$65,860
Medicare patients
263
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LupkynisVoclosporin11$160,525
TriumeqAbacavir/Dolutegravir/Lamivudi12$45,204
LokelmaSodium Zirconium Cyclosilicate19$18,171
Sevelamer Carbonate12$5,484
Calcium Acetate28$1,394
LevemirInsulin Detemir16$1,346
Calcitriol32$781
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$544
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$434
Lisinopril31$410
Atorvastatin Calcium30$295
Metoprolol Succinate15$256
Gabapentin18$219
Glipizide12$119
Amlodipine Besylate25$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aurinia Pharma U.S., Inc.Lupkynis$110$160,52511 claims
AstraZenecaLokelma$334$18,17119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,070 nephrology providers in Texas.

Other nephrology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →